European Commission predicts issuing recast proposals in early 2012; key EU committee created
This article was originally published in RAJ Devices
Executive Summary
European Commission proposals for the recast of the EU directives on medical devices, active implantable medical devices and in vitro diagnostics could be finalised by the beginning of 20121. In the meantime, another endeavour to have emerged from the recast deliberations has taken a step forward, after member states set up a Central Management Committee (CMC) that they envisage will support the resources-challenged commission in ensuring consistency in the implementation of the legal requirements throughout the EU.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.